No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.

Publication Title

Leukemia & lymphoma

Document Type

Article

Publication Date

12-10-2020

Keywords

Hemorrhage; PI3K inhibitor; anticoagulant; antiplatelet; thrombocytopenia

Abstract

The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This

Clinical Institute

Cancer

Specialty

Oncology

Share

COinS